

(12) PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. AU 199745667 B2
(10) Patent No. 731692

(54) Title
**Pharmaceutical preparation comprising eicosapentaenoic acid and/or
stearidonic acid**

(51)⁷ International Patent Classification(s)
A61K 031/20

(21) Application No: **199745667**

(22) Application Date: **1997.10.07**

(87) WIPO No: **WO98/16216**

(30) Priority Data

(31) Number	(32) Date	(33) Country
9621294	1996.10.11	GB
9626062	1996.12.16	GB

(43) Publication Date : **1998.05.11**

(43) Publication Journal Date : **1998.07.02**

(44) Accepted Journal Date : **2001.04.05**

(71) Applicant(s)
Scotia Holdings PLC

(72) Inventor(s)
David Frederick Horrobin

(74) Agent/Attorney
SPRUSON and FERGUSON,GPO Box 3898,SYDNEY NSW 2001

(56) Related Art
EP 347056
EP 454102
GB 2229363



(51) International Patent Classification ⁶ : A61K 31/20 // (A61K 31/20, 31:20)	A1	(11) International Publication Number: WO 98/16216
		(43) International Publication Date: 23 April 1998 (23.04.98)

(21) International Application Number: PCT/GB97/02738	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 7 October 1997 (07.10.97)	
(30) Priority Data: 9621294.9 11 October 1996 (11.10.96) GB 9626062.5 16 December 1996 (16.12.96) GB	Published <i>With international search report.</i>
(71) Applicant (for all designated States except US): SCOTIA HOLDINGS PLC [GB/GB]; Weyvern House, Weyvern Park, Portsmouth Road, Peasmarsh, Guildford, Surrey GU3 1NA (GB).	
(72) Inventor; and (75) Inventor/Applicant (for US only): HORROBIN, David, Frederick [GB/GB]; Scotia House, Castle Business Park, Stirling FK9 4TZ (GB).	
(74) Agent: FARWELL, William, Robert; Phillips & Leigh, 7 Staple Inn, Holborn, London WC1V 7QF (GB).	

(54) Title: PHARMACEUTICAL PREPARATION COMPRISING EICOSAPENTAENOIC ACID AND/OR STEARIDONIC ACID

(57) Abstract

A pharmaceutical preparation for the treatment of schizophrenia and/or tardive dyskinesia using an oil comprising eicosapentaenoic acid (EPA) and/or stearidonic acid (SA) in amounts of more than 20 %, preferably more than 40 % and very preferably more than 70 % by weight of the total (preferably of the total unsaturated) fatty acids present.

FIELD OF THE INVENTION

The invention relates to fatty acid treatment in schizophrenia.

Background

The essential fatty acids and their conversions in the body are shown in the following table.

n-6 EFAs		n-3 EFAs
18:2n-6 Linoleic acid (LA)		18:3n-3 α -linolenic acid (ALA)
↓	δ -6-desaturase	↓
18:3n-6 γ -Linolenic acid (GLA)		18:4n-3 Stearidonic acid, (SA)
↓	elongation	↓
20:3n-6 Dihomo- γ -linolenic acid (DGLA)		20:4n-3 Eicosatetraenoic acid
↓	δ -5-desaturase	↓
20:4n-6 Arachidonic acid (AA)		20:5n-3 Eicosapentaenoic acid (EPA)
↓	elongation	↓
22:4n-6 Adrenic acid (AdrA)		22:5n-3
↓	δ -4-desaturase	↓
22:5n-6		22:6n-3 Docosahexaenoic acid (DHA)

The acids, which in nature are of the all - cis configuration, are systematically named as derivatives of the corresponding octadecanoic, eicosanoic or docosanoic acids, e.g. LA z,z-octadeca - 9,12 - dienoic acid or DHA z,z,z,z,z - docosa- 4,7,10,13,16,19 - hexaenoic acid, but numerical designations based on the number of carbon atoms, the number of centres of unsaturation and the number of carbon atoms from the end of the chain to where the unsaturation begins, such as, correspondingly, 18:2 n-6 or 22:6 n-3, are convenient. Initials, e.g. EPA, and shortened forms of the name e.g. eicosapentaenoic acid, are used as trivial names in some instances.

In previous patent applications EPA-0347856 and EPA-0599576 we have drawn attention to the action of various essential fatty acids in schizophrenia and have claimed the use of these fatty acids in treatment. We have particularly drawn attention to the low red cell levels of arachidonic acid (AA) and docosahexaenoic acid (DHA) and to the use of these fatty acids.

Present Work

We have now unexpectedly found that one particular essential fatty acid which was previously accorded only a minor role is in fact particularly effective in treatment. This is eicosapentaenoic acid (EPA; 20:5n-3) which is present in the brain in only small amounts compared to AA and DHA. However, in a trial of treatment we have found that EPA is exceptionally effective in treatment of schizophrenia. Particularly effective are preparations comprising EPA in amounts of more than 20% of the total fatty acids present (preferably the total unsaturated fatty acids present), preferably more than 40% and very preferably more than 70%.

Studies of the use of omega-3 essential fatty acids in treatment, using a mixture of DHA and EPA, have previously shown modestly beneficial effects (Mellor et al, Human Psychopharmacology 11:39-46, 1996). The preparation used contained 18% of EPA and 12% of DHA and so far as this disclosure goes the therapeutic effects could have been caused by either component or both. An analysis of the relationship between fatty acid change and schizophrenia symptoms showed that a rise in the total omega-3 content of red cell membranes was associated with a fall in schizophrenic symptoms.

We therefore decided to try to determine the relative importance of EPA and DHA in schizophrenia. A study was carried out with 30 schizophrenia patients, most of whom had both positive and negative symptoms as shown by the positive and negative symptom scale (PANSS) and also had some evidence of tardive dyskinesia as shown by the abnormal involuntary movements scale (AIMS). Patients were randomly assigned on a double blind basis to treatment with 20ml of a placebo emulsion, 20ml of a 40% emulsion providing 8g of oil containing approximately 2.0g of EPA and 0.4g of DHA per day ('EPA group'), and 20ml of an emulsion providing approximately 2.3g of DHA and 0.5g of EPA per day ('DHA group') in 8g of oil. Patients were scored at baseline and at the end of 12 weeks of treatment. In the placebo group, 9 patients were unchanged or deteriorated on the PANSS and AIMS scores and one improved. In the DHA group, seven patients were unchanged or deteriorated and three patients improved. In contrast, in the EPA group one patient was unchanged but nine patients showed improvement. The improvement was seen in both the negative and positive symptom scores and in the AIMS score. There was therefore a broad spectrum improvement in all aspects of the schizophrenia syndrome. The DHA group was not significantly different from placebo whereas the EPA group was significantly better than both the DHA group and the placebo group ($p < 0.02$ in both cases).

It is therefore possible to conclude that the main therapeutic effect of treatment with EFAs is attributable to the effect of EPA. The other EFAs may contribute to some degree but there can be no doubt that EPA is primarily responsible for the positive effects of treatment with omega-3 EFA preparations. We concluded that EPA should also be effective in other psychiatric disorders such as Alzheimer's disease and depression since low levels of n-3 fatty acids have been shown in the blood and/or the brain of patients with these disorders also. Two patients with severe depression not responsive to the usual anti-depressants were therefore treated with the EPA formulation as used in the schizophrenia trial. Within 4 weeks both had shown remarkable improvement in their symptoms.

While we cannot be certain of the mechanism by which EPA is working, one possibility is that it is inhibiting the enzyme, phospholipase A₂. There is considerable evidence that phospholipase (PL) A₂ activity is elevated in schizophrenia (Horrobin et al, Schizophrenia Research 1994; 13: 195-207). Compounds which safely inhibit PLA₂ might therefore be expected to have a therapeutic effect. In in vitro studies of the effects of fatty acids on PLA₂ activity we have found that EPA is a potent inhibitor, whereas the relatively similar fatty acid, DHA is not. This might explain why DHA did not prove effective in the clinical studies.

We have further found that another n-3 fatty acid, stearidonic acid (18:4 n-3), is as effective in inhibiting PLA₂ as is EPA. EPA and SA are 20- and 18- carbon fatty acids which have in fact been shown to inhibit the activity of phospholipase A₂ (Finnen, Biochem Soc. Trans 1991; 19:915). In contrast, DHA is a 22-carbon fatty acid which like other 22-carbon acids does not inhibit phospholipase. This may offer an explanation for the differences between EPA and DHA since there is evidence for overactivity of phospholipase A₂ in schizophrenia. We therefore propose that stearidonic acid will be effective in treating schizophrenia and the other disorders and we include its use for that purpose alone or with EPA.

The n-6 EFAs such as linoleic acid, gammalinolenic acid (GLA) dihomogammalinolenic acid (DOLA) and arachidonic acid (AA) are important in brain structure. GLA can be metabolised to DGLA and AA. We therefore tried to see whether the addition of an oil containing linoleic acid and GLA would be beneficial in two individuals who had responded to EPA. In fact their condition appeared to be less good with addition of the n-6 EFAs. It is therefore better to treat with EPA preparations in which the levels of n-6 EFAs are kept at a low level compared to the concentration of EPA. Either n-6 EFAs should be absent or if present at a ratio to EPA of not more than 1:3, preferably 1:4 or less.

In any case to ensure that the effects secured are not countered the weight ratio of SA/EPA to any DHA present is desirably not less than 3:1 by weight and desirably 4:1 or more.


Statement of Invention

According to a first aspect, the present invention consists in the use of an oil comprising eicosapentaenoic acid (EPA) and/or stearidonic acid (SA) in amounts of more than 20% by weight of the total fatty acids present in the manufacture of a medicament for the treatment or prophylaxis of schizophrenia, tardive dyskinesia, depression, Alzheimer's disease or other dementias and wherein the weight ratio of SA/EPA to any n-6 EFAs present is not less than 3:1 or n-6 EFAs are absent.

According to a second aspect, the present invention consists in a method for the treatment or prophylaxis of schizophrenia, tardive dyskinesia, depression, Alzheimer's disease or other dementias in a mammal requiring said treatment or prophylaxis, which method includes or consists of administering to said mammal an effective amount of an oil comprising eicosapentaenoic acid (EPA) and/or stearidonic acid (SA) in amounts of more than 20% by weight of the total fatty acids present and wherein the weight ratio of SA/EPA to any n-6 EFAs present is not less than 3:1 or n-6 EFAs are absent.

According to a third aspect, the present invention consists in an oil comprising eicosapentaenoic acid (EPA) and/or stearidonic acid (SA) in amounts of more than 20% by weight of the total fatty acids present and wherein the weight ratio of SA/EPA to any n-6 EFAs is not less than 3:1 or n-6 EFAs are absent, when used in the treatment or prophylaxis of schizophrenia, tardive dyskinesia, depression, Alzheimer's disease or other dementias.

According to a fourth aspect, the present invention consists in a method for the treatment or prophylaxis of schizophrenia, tardive dyskinesia, depression, Alzheimer's disease or other dementias in a mammal requiring said treatment or prophylaxis, which



method includes or consists of administering to said mammal an effective amount of a pharmaceutical preparation including an oil comprising eicosapentaenoic acid (EPA) and/or stearidonic acid (SA) in amounts of more than 20% by weight of the total fatty acids present and wherein the weight ratio of SA/EPA to any n-6 EFAs is not less than 3:1 or n-6 EFAs are absent.

According to a fifth aspect, the present invention consists in a pharmaceutical preparation using an oil comprising eicosapentaenoic acid (EPA) and/or stearidonic acid (SA) in amounts of more than 20% by weight of the total fatty acids present and wherein the weight ratio of SA/EPA to any n-6 EFAs present is not less than 3:1 or n-6 EFAs are absent, when used in the treatment or prophylaxis of schizophrenia, tardive dyskinesia, depression, Alzheimer's disease or other dementias.

According to a sixth aspect, the present invention consists in a pharmaceutical preparation using an oil comprising stearidonic acid (SA) or stearidonic acid in combination with eicosapentaenoic acid (EPA) in amounts of more than 20% by weight of the total fatty acids present and wherein the weight ratio of SA or SA in combination with EPA to any n-6 EFAs present is not less than 3:1 or n-6 EFAs are absent.

The invention is set out in the claims herein but inter alia provides a pharmaceutical preparation for the treatment of schizophrenia and/or tardive dyskinesia using an oil comprising eicosapentaenoic acid (EPA) and/or stearidonic acid (SA) in amounts of more than 20%, preferably more than 40% and very preferably more than 70% by weight of the total (preferably of the total unsaturated) fatty acids present and wherein the weight ratio of SA/EPA to n-6 EFAs present is not less than 3:1 and is preferably 4:1 or more, or n-6 EFAs are absent. Corresponding methods of treatment, and methods of preparation of medicaments, wherein such oils as used, are also within the invention, as are corresponding treatments of depression or Alzheimer's disease or other dementias.

The EPA can be provided in any appropriate way which will elevate the levels of EPA in the blood. Mono-, di-, and tri-glycerides, mono- or di-esters, salts, cholesterol esters, amides, phospholipids, free acids or any other appropriate form may be used to deliver the



EPA. Mono or diesters of EPA as specified in previous applications where the present inventor is a co-inventor (PCT/GB96/01052 and 01053), published respectively as WO96/34855 and WO96/34846 are particularly convenient forms in which the EPA may be administered. The EPA may be derived from fish or marine mammal oils, microbial oils or even from total chemical synthesis. The EPA dose used may range from 10mg to 100g/day, preferably 100mg to 20g/day and very preferably from 500mg to 10g/day. Oral, enteral, parenteral, topical, or any other appropriate route of administration may be used. Stearidonic acid may be provided in similar doses and in similar ways, alone or with the EPA

Examples

The study described above illustrates treatment according to the invention but examples of suitable formulations are as follows:-

1. Soft gelatine capsules, each containing 200mg of EPA in the form of one of the following:
 - a) An oil containing 22% EPA derived from marine or microbial sources.
 - b) An oil containing 56% EPA derived from marine or microbial sources.
 - c) An oil containing 75% of EPA derived from marine or microbial sources.
 - d) An oil containing 95% of EPA derived from marine, microbial or synthetic sources.
 - e) EPA 1-3 propane diol diester.

2. Oils as in examples 1a to 1e but formulated as an emulsion for oral administration. The emulsion may contain 5 to 50% of the oil emulsified with emulsifying agents known to those skilled in the art including natural, synthetic and semi-synthetic agents such as phospholipids and galactolipids, the latter for example as described in PCT SE95/00115 published as WO95/20943.

3. Emulsions as in 2 but sterilised and appropriately formulated for intravenous administration.
4. Oils as in examples 1a to 1e, sterilised and formulated for intramuscular or sub-cutaneous injection.
5. Oils as in examples 1a to 1e formulated for topical administration using patch or other technologies known to those skilled in the art.
- 6-10. As Examples 1-5 except that stearidonic acid is used instead of EPA or in admixture with it e.g. half and half.

The claims defining the invention are as follows:

1. The use of an oil comprising eicosapentaenoic acid (EPA) and/or stearidonic acid (SA) in amounts of more than 20% by weight of the total fatty acids present in the manufacture of a medicament for the treatment or prophylaxis of schizophrenia, tardive
5 dyskinesia, depression, Alzheimer's disease or other dementias and wherein the weight ratio of SA/EPA to any n-6 EFAs present is not less than 3:1 or n-6 EFAs are absent.

2. The use according to claim 1 wherein the EPA and/or SA are present in amounts of more than 20% by weight of the total unsaturated fatty acids present.

3. The use according to claim 1 wherein the EPA and/or SA are present in
10 amounts of more than 40% by weight of the total fatty acids present.

4. The use according to claim 1 wherein the EPA and/or SA are present in amounts of more than 40% by weight of the total unsaturated fatty acids present.

5. The use according to claim 1 wherein the EPA and/or SA are present in amounts of more than 70% by weight of the total fatty acids present.

6. The use according to claim 1 wherein the EPA and/or SA are present in
15 amounts of more than 70% by weight of the total unsaturated fatty acids present.

7. The use according to any one of claims 1 to 6 wherein the weight ratio of SA/EPA to n-6 EFAs present is 4:1 or more.

8. The use according to any one of claims 1 to 7 wherein the weight ratio of
20 SA/EPA to any DHA present is not less than 3:1.

9. The use according to claim 8 wherein the weight ratio of SA/EPA to any DHA present is 4:1 or more.

10. The use according to any one of claims 1 to 9 wherein n-6 EFAs are absent.

11. The use according to any one of claims 1 to 10 wherein 10mg to 100g of EPA
25 and/or SA is administered daily.

12. The use according to claim 11 wherein 100mg to 20g of EPA and/or SA is administered daily.

13. The use according to claim 11 wherein 500mg to 10g of EPA and/or SA is administered daily.

30 14. The use according to any one of claims 1 to 13, substantially as hereinbefore described with reference to any one of the examples.

15. A method for the treatment or prophylaxis of schizophrenia, tardive dyskinesia, depression, Alzheimer's disease or other dementias in a mammal requiring said treatment or prophylaxis, which method includes or consists of administering to said mammal an effective amount of an oil comprising eicosapentaenoic acid (EPA) and/or



stearidonic acid (SA) in amounts of more than 20% by weight of the total fatty acids present and wherein the weight ratio of SA/EPA to any n-6 EFAs present is not less than 3:1 or n-6 EFAs are absent.

16. A method according to claim 15 wherein the EPA and/or SA are present in amounts of more than 20% by weight of the total unsaturated fatty acids present.

17. A method according to claim 15 wherein the EPA and/or SA are present in amounts of more than 40% by weight of the total fatty acids present.

18. A method according to claim 15 wherein the EPA and/or SA are present in amounts of more than 40% by weight of the total unsaturated fatty acids present.

19. A method according to claim 15 wherein the EPA and/or SA are present in amounts of more than 70% by weight of the total fatty acids present.

20. A method according to claim 15 wherein the EPA and/or SA are present in amounts of more than 70% by weight of the total unsaturated fatty acids present.

21. A method according to any one of claims 15 to 20 wherein the weight ratio of SA/EPA to n-6 EFAs present is 4:1 or more.

22. A method according to any one of claims 15 to 21 wherein the weight ratio of SA/EPA to any DHA present is not less than 3:1.

23. A method according to claim 22 wherein the weight ratio of SA/EPA to any DHA present is 4:1 or more.

24. A method according to any one of claims 15 to 23 wherein n-6 EFAs are absent.


25. A method according to any one of claims 15 to 24 wherein 10mg to 100g of EPA and/or SA is administered daily.

26. A method according to claim 25 wherein 100mg to 20g of EPA and/or SA is administered daily.

27. A method according to claim 25 wherein 500mg to 10g of EPA and/or SA is administered daily.

28. An oil comprising eicosapentaenoic acid (EPA) and/or stearidonic acid (SA) in amounts of more than 20% by weight of the total fatty acids present and wherein the weight ratio of SA/EPA to any n-6 EFAS is not less than 3:1 or n-6 EFAs are absent, when used in the treatment or prophylaxis of schizophrenia, tardive dyskinesia, depression, Alzheimer's disease or other dementias.

29. An oil according to claim 28 wherein the EPA and/or SA are present in amounts of more than 20% by weight of the total unsaturated fatty acids present.



30. An oil according to claim 28 wherein the EPA and/or SA are present in amounts of more than 40% by weight of the total fatty acids present.

31. An oil according to claim 28 wherein the EPA and/or SA are present in amounts of more than 40% by weight of the total unsaturated fatty acids present.

5 32. An oil according to claim 28 wherein the EPA and/or SA are present in amounts of more than 70% by weight of the total fatty acids present.

33. An oil according to claim 28 wherein the EPA and/or SA are present in amounts of more than 70% by weight of the total unsaturated fatty acids present.

10 34. An oil according to any one of claims 28 to 33 wherein the weight ratio of SA/EPA to n-6 EFAs present is 4:1 or more.

35. An oil according to any one of claims 28 to 34 wherein the weight ratio of SA/EPA to any DHA present is not less than 3:1.

36. An oil according to claim 35 wherein the weight ratio of SA/EPA to any DHA present is 4:1 or more.

15 37. An oil according to any one of claims 28 to 36 wherein n-6 EFAs are absent.

38. An oil according to any one of claims 28 to 37 wherein 10mg to 100g of EPA and/or SA is administered daily.

39. An oil according to claim 38 wherein 100mg to 20g of EPA and/or SA is administered daily.

20 40. An oil according to claim 38 wherein 500mg to 10g of EPA and/or SA is administered daily.

41. A method for the treatment or prophylaxis of schizophrenia, tardive dyskinesia, depression, Alzheimer's disease or other dementias in a mammal requiring said treatment or prophylaxis, which method includes or consists of administering to said mammal an effective amount of a pharmaceutical preparation including an oil comprising
25 eicosapentaenoic acid (EPA) and/or stearidonic acid (SA) in amounts of more than 20% by weight of the total fatty acids present and wherein the weight ratio of SA/EPA to any n-6 EFAs is not less than 3:1 or n-6 EFAs are absent.

30 42. A method according to claim 41 wherein the EPA and/or SA are present in amounts of more than 20% by weight of the total unsaturated fatty acids present.

43. A method according to claim 41 wherein the EPA and/or SA are present in amounts of more than 40% by weight of the total fatty acids present.

44. A method according to claim 41 wherein the EPA and/or SA are present in amounts of more than 40% by weight of the total unsaturated fatty acids present.



45. A method according to claim 41 wherein the EPA and/or SA are present in amounts of more than 70% by weight of the total fatty acids present.

46. A method according to claim 41 wherein the EPA and/or SA are present in amounts of more than 70% by weight of the total unsaturated fatty acids present.

5 47. A method according to any one of claims 41 to 46 wherein the weight ratio of SA/EPA to n-6 EFAs present is 4:1 or more.

48. A method according to any one of claims 41 to 47 wherein the weight ratio of SA/EPA to any DHA present is not less than 3:1.

10 49. A method according to claim 48 wherein the weight ratio of SA/EPA to any DHA present is 4:1 or more.

50. A method according to any one of claims 41 to 49 wherein n-6 EFAs are absent.

51. A method according to any one of claims 41 to 50 wherein 10mg to 100g of EPA and/or SA is administered daily.

15 52. A method according to claim 51 wherein 100mg to 20g of EPA and/or SA is administered daily.

53. A method according to claim 51 wherein 500mg to 10g of EPA and/or SA is administered daily.

20 54. A pharmaceutical preparation using an oil comprising eicosapentaenoic acid (EPA) and/or stearidonic acid (SA) in amounts of more than 20% by weight of the total fatty acids present and wherein the weight ratio of SA/EPA to any n-6 EFAs present is not less than 3:1 or n-6 EFAs are absent, when used in the treatment or prophylaxis of schizophrenia, tardive dyskinesia, depression, Alzheimer's disease or other dementias.

25 55. A pharmaceutical preparation according to claim 54 wherein the EPA and/or SA is present in amounts of more than 20% of the total unsaturated fatty acids present.

56. A pharmaceutical preparation according to claim 54 wherein the EPA and/or SA is present in amounts of more than 40% by weight of the total fatty acids present.

30 57. A pharmaceutical preparation according to claim 54 wherein the EPA and/or SA is present in amounts of more than 40% by weight of the total unsaturated fatty acids present.

58. A pharmaceutical preparation according to claim 54 wherein the EPA and/or SA is present in amounts of more than 70% by weight of the total fatty acids present.

59. A pharmaceutical preparation according to claim 54 wherein the EPA and/or SA is present in amounts of more than 70% by weight of the total unsaturated fatty acids present.



60. A pharmaceutical preparation according to any one of claims 54 to 59 wherein the weight ratio of SA/EPA to n-6 EFAs present is 4:1 or more.

61. A pharmaceutical preparation according to any one of claims 54 to 60 wherein the weight ratio of SA/EPA to any DHA present is not less than 3:1.

5 62. A pharmaceutical preparation according to claim 61 wherein the weight ratio of SA/EPA to any DHA present is 4:1 or more.

63. A pharmaceutical preparation according to any one of claims 54 to 62 wherein n-6 EFAs are absent.

64. A pharmaceutical preparation according to any one of claims 54 to 63
10 wherein 10mg to 100g of EPA and/or SA is administered daily.

65. A pharmaceutical preparation according to claim 64 wherein 100mg to 20g of EPA and/or SA is administered daily.

66. A pharmaceutical preparation according to claim 64 wherein 500mg to 10g of EPA and/or SA is administered daily.

15 67. A pharmaceutical preparation using an oil comprising stearidonic acid (SA) or stearidonic acid in combination with eicosapentaenoic acid (EPA) in amounts of more than 20% by weight of the total fatty acids present and wherein the weight ratio of SA or SA in combination with EPA to any n-6 EFAs present is not less than 3:1 or n-6 EFAs are absent.

20 68. A pharmaceutical preparation according to claim 67 wherein the SA or SA in combination with EPA are present in amounts of more than 20% of the total unsaturated fatty acids present.

69. A pharmaceutical preparation according to claim 67 wherein the SA or SA in combination with EPA are present in amounts of more than 40% by weight of the total
25 fatty acids present.

70. A pharmaceutical preparation according to claim 67 wherein the SA or SA in combination with EPA are present in amounts of more than 40% by weight of the total unsaturated fatty acids present.

71. A pharmaceutical preparation according to claim 67 wherein the SA or SA in combination with EPA are present in amounts of more than 70% by weight of the total
30 fatty acids present.

72. A pharmaceutical preparation according to claim 67 wherein the SA or SA in combination with EPA are present in amounts of more than 70% by weight of the total unsaturated fatty acids present.



73. A pharmaceutical preparation according to any one of claims 67 to 72 wherein the weight ratio of SA or SA in combination with EPA to n-6 EFAs present is 4:1 or more.

74. A pharmaceutical preparation according to any one of claims 67 to 63 wherein the weight ratio of SA or SA in combination with EPA to any DHA present is not less than 3:1.

75. A pharmaceutical preparation according to claim 74 wherein the weight ratio of SA or SA in combination with EPA to any DHA present is 4:1 or more.

76. A pharmaceutical preparation according to any one of claims 67 to 75 wherein n-6 EFAs are absent.

77. A pharmaceutical preparation according to any one of claims 67 to 76 wherein 10mg to 100g of SA or SA in combination with EPA is administered daily.

78. A pharmaceutical preparation according to claim 77 wherein 100mg to 20g of SA or SA in combination with EPA is administered daily.

79. A pharmaceutical preparation according to claim 77 wherein 500mg to 10g of SA or SA in combination with EPA is administered daily.

80. A pharmaceutical preparation according to any one of claims 67 to 79 substantially as hereinbefore described with reference to any one of the examples.

81. A method for the treatment or prophylaxis of schizophrenia, tardive dyskinesia, depression, Alzheimer's disease or other dementias in a mammal requiring said treatment or prophylaxis, which method includes or consists of administering to said mammal an effective amount of an oil or a pharmaceutical preparation comprising said oil, said oil and pharmaceutical preparation being substantially as hereinbefore described with reference to any one of the examples.

82. An oil substantially as hereinbefore described with reference to any one of the examples when used in the treatment or prophylaxis of schizophrenia, tardive dyskinesia, depression, Alzheimer's disease or other dementias.

Dated 4 January, 2001

Scotia Holdings Plc

Patent Attorneys for the Applicant/Nominated Person

SPRUSON & FERGUSON

